NCT03682276View on ClinicalTrials.gov

Safety and Bioactivity of Ipilimumab and Nivolumab Combination Prior to Liver Resection in Hepatocellular Carcinoma

PHASE1/PHASE2UnknownINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

March 1, 2019

Primary Completion Date

September 1, 2023

Study Completion Date

December 1, 2023

Conditions
Hepatocellular Carcinoma
Interventions
BIOLOGICAL

Ipilimumab

Ipilimumab is a monoclonal antibody given as an immunotherapy

BIOLOGICAL

Nivolumab

Nivolumab is a monoclonal antibody given as an immunotherapy

Trial Locations (1)

W12 0HS

RECRUITING

Imperial College Healthcare NHS Trust, London

Sponsors

Collaborators (1)

Bristol-Myers Squibb
All Listed Sponsors
collaborator

Bristol-Myers Squibb

INDUSTRY

lead

Imperial College London

OTHER

NCT03682276 - Safety and Bioactivity of Ipilimumab and Nivolumab Combination Prior to Liver Resection in Hepatocellular Carcinoma | Biotech Hunter | Biotech Hunter